Regulus Therapeutics (NASDAQ:RGLS) Earns “Buy” Rating from HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

RGLS has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Trading Down 6.4 %

NASDAQ RGLS opened at $1.46 on Wednesday. The business’s fifty day moving average is $1.59 and its 200-day moving average is $1.87. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). Equities analysts predict that Regulus Therapeutics will post -0.8 EPS for the current year.

Institutional Trading of Regulus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in shares of Regulus Therapeutics during the third quarter valued at about $26,000. SG Americas Securities LLC purchased a new position in Regulus Therapeutics during the third quarter valued at approximately $33,000. Rhumbline Advisers bought a new stake in Regulus Therapeutics during the 2nd quarter worth approximately $136,000. Tyche Wealth Partners LLC lifted its stake in Regulus Therapeutics by 920.6% in the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 95,694 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.